Experts: Professor Timothy Hughes SAHMRI / SA Pathology, University of Adelaide (Australia) Professor Dominik Wolf Department of Hematology and Oncology, Comprehensive Cancer Centre, Medical University Innsbruck (Austria)

Program:
Overview of selected oral presentations during the meeting:

Biological highlights:

• High-throughout evaluation of the potential of cancer drugs to enhance natural killer cell immunotherapy in CML (Nygren P et al, EHA 2022)
• SETD2/H3K36ME3 deficiency sustains genomic instability and enhances clonogenic potential of CML progenitors (Mancini M et al, EHA 2022)
• Biology and function of cirucular PCMDT1 in CML in blast crisis (Urs AP et al, EHA 2022)

Clinical highlights:

• Efficacy and safety results from ASCEMBL, a phase 3 study of Asciminib vs Bosutinib in patients with CML ≥ 2 prior TKIs: Week 96 update (Réa D et al, EHA 2022)
• International, prospective study comparing Nilotinib versus Imatinib with early switch to Nilotinib to obtain sustained TFR in patients with CML: The first Interim Report (Pane F et al, EHA 2022)
• BCR:ABL1 digital PCR identifies chronic phase CML patients suitable for an early TKI discontinuation attempt: a patient-level meta-analysis (Kockerols C et al, EHA 2022)
• Final results of TKI discontinuation trial with Dasatinib for second attempt of TFR (TFR2) after failing first attempts with Imatinib (TRAD trial) (Kim D et al, EHA 2022)

If you have any questions or comments to the speakers, please email info@cml-foundation.org.